HC Wainwright Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $50.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price decreased by HC Wainwright from $60.00 to $50.00 in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q1 2026 earnings at ($1.55) EPS, Q2 2026 earnings at ($1.20) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($4.05) EPS, Q1 2027 earnings at $0.28 EPS, Q2 2027 earnings at $1.19 EPS, Q3 2027 earnings at $1.55 EPS, Q4 2027 earnings at $2.64 EPS and FY2027 earnings at $5.66 EPS.

Other analysts have also issued reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Barclays cut their target price on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, November 24th. Wells Fargo & Company decreased their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 30th. Truist Financial cut their price target on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Finally, Jefferies Financial Group dropped their price objective on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research note on Tuesday, December 30th. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $68.29.

Ultragenyx Pharmaceutical Trading Up 6.7%

RARE stock opened at $21.83 on Tuesday. Ultragenyx Pharmaceutical has a 12-month low of $18.41 and a 12-month high of $45.00. The company has a market cap of $2.11 billion, a PE ratio of -3.74 and a beta of 0.16. The stock has a 50-day moving average price of $25.67 and a two-hundred day moving average price of $29.54.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 566.58%. The company had revenue of $207.28 million during the quarter, compared to analysts’ expectations of $199.60 million. During the same period last year, the business earned ($1.39) earnings per share. The company’s revenue for the quarter was up 25.5% compared to the same quarter last year. Equities analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Howard Horn sold 3,061 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $23.56, for a total transaction of $72,117.16. Following the transaction, the chief financial officer directly owned 88,935 shares of the company’s stock, valued at approximately $2,095,308.60. This trade represents a 3.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 6,227 shares of company stock valued at $187,126. 5.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of large investors have recently bought and sold shares of RARE. Alberta Investment Management Corp acquired a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth $883,000. Mercer Global Advisors Inc. ADV lifted its stake in Ultragenyx Pharmaceutical by 17.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,965 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 2,036 shares during the period. Krensavage Asset Management LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $3,442,000. Empowered Funds LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at about $66,000. Finally, XTX Topco Ltd boosted its stake in Ultragenyx Pharmaceutical by 734.8% during the 4th quarter. XTX Topco Ltd now owns 119,996 shares of the biopharmaceutical company’s stock valued at $2,760,000 after purchasing an additional 105,622 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright raised multiple 2026–2027 EPS forecasts, lifted several quarterly estimates and reiterated a Buy rating with a $50 price target — a bullish research view that supports potential upside if clinical/commercial execution meets their forecast. HC Wainwright coverage
• Neutral Sentiment: Canaccord cut its price target from $128 to $79 but kept a Buy rating; the lowered target reduces the analyst-implied upside even though the stance remains constructive. Canaccord note
• Neutral Sentiment: Wedbush reiterated a Neutral rating on RARE, providing little near?term catalyst from that shop. Wedbush note
• Negative Sentiment: Multiple plaintiffs’ law firms have filed or are soliciting class members in a securities?fraud suit (class period alleged: Aug 3, 2023–Dec 26, 2025) and are reminding investors of an April 6, 2026 lead?plaintiff deadline. The filings allege material misstatements/omissions tied to setrusumab and create legal and settlement risk — a clear overhang that can pressure the stock while the case progresses. Representative notices: Pomerantz (PR Newswire), Robbins Geller (PR Newswire), Levi & Korsinsky (GlobeNewsWire). Pomerantz notice Robbins Geller notice Levi & Korsinsky notice

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.